Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024
China-based Antengene Corporation Limited (Antengene, HKG: 6996) announced the presentation of the latest results from...
Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...
NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao
The National Medical Products Administration (NMPA) has issued the “Notification on Simplifying the Registration and...
China’s NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism
The National Healthcare Security Administration (NHSA) and National Health Commission (NHC) of China have released...
CSPC Pharmaceutical Group’s SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that the National Medical Products...
GSK’s Nucala Receives FDA Review for COPD Indication Based on MATINEE Study Data
UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that the US Food and Drug Administration...
Hantech Medical Device Co., Ltd Acquires BD’s Villamarzana Factory to Expand Manufacturing
China-based Hantech Medical Device Co., Ltd, a Contract Development Manufacturing Organization (CDMO) specializing in medical...
Precision Biotech and T&L Biotechnology Form Partnership to Advance Cell and Gene Therapies
China-based Precision Biotech has announced a strategic partnership with compatriot firm T&L Biotechnology Co., Ltd....
MicroPort Scientific Corp. Launches FireFalcon Balloon for Coronary Interventions with NMPA Approval
Shanghai-based medical device giant MicroPort Scientific Corp., (HKG: 0853) has announced that it has received...
HuidaGene Therapeutics Initiates HERO Trial for RNA-Editing Therapy HG204 in MECP2 Duplication Syndrome
Shanghai-based HuidaGene Therapeutics has announced the first subject dosing of the HERO clinical trial, which...
Simcere Pharmaceutical’s SIM0508 Reaches First Patient Dosing in Global Clinical Study
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced the first patient...
Livzon Pharmaceutical Group Inks Influenza Vaccine Patent Deal with South China Vaccine Corporation
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has entered into a significant patent and technology...
WuXi AppTec’s Subsidiary Invests EUR 20 Million in Jeito II S.L.P. for Growth Expansion
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced...
TJ Biopharma and Jumpcan Pharmaceutical Announce NMPA Review of Eftansomatropin Alfa BLA
Chinese partners TJ Biopharma and Jumpcan Pharmaceutical (SHA: 600566) have jointly announced that the National...
AstraZeneca’s Imfinzi Receives FDA Priority Review for Muscle-Invasive Bladder Cancer
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that the US Food and Drug...
Amgen’s Blincyto Meets Primary Endpoint in Phase III AALL1731 Study for Pediatric B-ALL
US-based biotechnology company Amgen (NASDAQ: AMGN) has published the results from the Phase III study...
Novartis’ Fabhalta Demonstrates Positive Results in APPULSE-PNH Phase IIIb Study
Swiss pharmaceutical major Novartis (NYSE: NVS) has released positive topline results from the APPULSE-PNH Phase...
Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion
China-based Jiaxing Pharbers Genesis has reportedly raised RMB 100 million (USD 13.74 million) in a...
Novo Holdings’ Acquisition of Catalent Gets EU Nod, Paving Way for Novo Nordisk Expansion
The acquisition of contract development and manufacturing organization (CDMO) Catalent (NYSE: CTLT) by Novo Holdings...
Johnson & Johnson’s Darzalex Faspro Showcases Clinical Efficacy in Multiple Myeloma at ASH 2024
US healthcare conglomerate Johnson & Johnson (J&J, NYSE: JNJ) has presented results from several clinical...